These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20440227)

  • 21. The pharmacogenomics of clopidogrel.
    Levitt MR; Osbun JW; Kim LJ
    World Neurosurg; 2012; 77(3-4):406-7. PubMed ID: 22366366
    [No Abstract]   [Full Text] [Related]  

  • 22. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 24. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Miao J; Liu R; Li Z
    Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
    [No Abstract]   [Full Text] [Related]  

  • 26. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with clopidogrel nonresponsiveness.
    Momary KM; Dorsch MP
    Future Cardiol; 2010 Mar; 6(2):195-210. PubMed ID: 20230261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?
    Knauer MJ; Diamandis EP; Hulot JS; Kim RB; So DY
    Clin Chem; 2015 Oct; 61(10):1235-40. PubMed ID: 26272232
    [No Abstract]   [Full Text] [Related]  

  • 29. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
    Ellis KJ; Stouffer GA; McLeod HL; Lee CR
    Pharmacogenomics; 2009 Nov; 10(11):1799-817. PubMed ID: 19891556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics and its relevance to clinical practice.
    Sutiman N; Chowbay B
    Ann Acad Med Singap; 2013 Sep; 42(9):429-31. PubMed ID: 24162316
    [No Abstract]   [Full Text] [Related]  

  • 31. [Genetic variability in the efficacy of clopidogrel].
    Kristensen KE; Rasmussen HB; Hansen PR
    Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPI interactions with clopidogrel revisited.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):13-4. PubMed ID: 19229161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
    Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
    Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.
    Hasan MS; Basri HB; Hin LP; Stanslas J
    Int J Neurosci; 2013 Mar; 123(3):143-54. PubMed ID: 23110469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Jeong YH; Park Y; Kim IS
    JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?
    Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):147-50. PubMed ID: 20166430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
    Hulot JS; Bura A; Villard E; Azizi M; Remones V; Goyenvalle C; Aiach M; Lechat P; Gaussem P
    Blood; 2006 Oct; 108(7):2244-7. PubMed ID: 16772608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
    Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.